ECSP22061867A - Moléculas de unión a antígeno contra alppl2 y/o alpp y usos de las mismas - Google Patents
Moléculas de unión a antígeno contra alppl2 y/o alpp y usos de las mismasInfo
- Publication number
- ECSP22061867A ECSP22061867A ECSENADI202261867A ECDI202261867A ECSP22061867A EC SP22061867 A ECSP22061867 A EC SP22061867A EC SENADI202261867 A ECSENADI202261867 A EC SENADI202261867A EC DI202261867 A ECDI202261867 A EC DI202261867A EC SP22061867 A ECSP22061867 A EC SP22061867A
- Authority
- EC
- Ecuador
- Prior art keywords
- alppl2
- antigen
- binding molecules
- alpp
- relates
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3046—Stomach, Intestines
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/5753—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the stomach or small intestine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/72—Increased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/916—Hydrolases (3) acting on ester bonds (3.1), e.g. phosphatases (3.1.3), phospholipases C or phospholipases D (3.1.4)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SG10202001139U | 2020-02-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP22061867A true ECSP22061867A (es) | 2022-09-30 |
Family
ID=77199411
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ECSENADI202261867A ECSP22061867A (es) | 2020-02-07 | 2022-08-08 | Moléculas de unión a antígeno contra alppl2 y/o alpp y usos de las mismas |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US20230080224A1 (https=) |
| EP (1) | EP4100443A4 (https=) |
| JP (2) | JP2023512827A (https=) |
| KR (1) | KR20220139930A (https=) |
| CN (1) | CN115380050A (https=) |
| AU (1) | AU2021217919A1 (https=) |
| BR (1) | BR112022015540A2 (https=) |
| CA (1) | CA3170141A1 (https=) |
| CL (3) | CL2022002114A1 (https=) |
| CO (1) | CO2022011944A2 (https=) |
| CR (1) | CR20220441A (https=) |
| DO (2) | DOP2022000159A (https=) |
| EC (1) | ECSP22061867A (https=) |
| IL (1) | IL295291A (https=) |
| JO (1) | JOP20220175A1 (https=) |
| MX (1) | MX2022009709A (https=) |
| PE (1) | PE20221781A1 (https=) |
| PH (1) | PH12022552038A1 (https=) |
| WO (1) | WO2021158178A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN120882866A (zh) * | 2022-12-21 | 2025-10-31 | 阿尔麦克探索有限公司 | Alpp特异性变体抗原结合分子 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0624500D0 (en) * | 2006-12-07 | 2007-01-17 | Istituto Superiore Di Sanito | A novel passive vaccine for candida infections |
| BRPI0914251B1 (pt) * | 2008-06-25 | 2022-07-19 | Novartis Ag | Imunoligante recombinante, seu fragmento de ligação ao antígeno, uso dos mesmos, e composição |
| CA2874083C (en) * | 2014-12-05 | 2024-01-02 | Universite Laval | Tdp-43-binding polypeptides useful for the treatment of neurodegenerative diseases |
| SI3383920T1 (sl) * | 2015-11-30 | 2024-06-28 | The Regents Of The University Of California | Dostava tumorsko specifičnega koristnega tovora in imunska aktivacija z uporabo humanega protitelesa, ki cilja visoko specifičen površinski antigen tumorskih celic |
| JP2019131471A (ja) * | 2016-05-27 | 2019-08-08 | 国立大学法人 東京大学 | 抗ＴＧＦ−ｂｅｔａ３抗体およびその使用 |
| CN108088997B (zh) * | 2016-11-21 | 2020-03-17 | 同济大学 | 利用细胞表面分子标志物鉴定人类原态多能性的方法 |
-
2021
- 2021-02-05 US US17/798,025 patent/US20230080224A1/en active Pending
- 2021-02-05 JP JP2022548123A patent/JP2023512827A/ja active Pending
- 2021-02-05 IL IL295291A patent/IL295291A/en unknown
- 2021-02-05 MX MX2022009709A patent/MX2022009709A/es unknown
- 2021-02-05 AU AU2021217919A patent/AU2021217919A1/en active Pending
- 2021-02-05 PH PH1/2022/552038A patent/PH12022552038A1/en unknown
- 2021-02-05 PE PE2022001547A patent/PE20221781A1/es unknown
- 2021-02-05 CR CR20220441A patent/CR20220441A/es unknown
- 2021-02-05 CN CN202180017750.8A patent/CN115380050A/zh active Pending
- 2021-02-05 BR BR112022015540A patent/BR112022015540A2/pt unknown
- 2021-02-05 WO PCT/SG2021/050061 patent/WO2021158178A1/en not_active Ceased
- 2021-02-05 KR KR1020227030781A patent/KR20220139930A/ko active Pending
- 2021-02-05 EP EP21751256.5A patent/EP4100443A4/en active Pending
- 2021-02-05 CA CA3170141A patent/CA3170141A1/en active Pending
-
2022
- 2022-07-28 JO JOP/2022/0175A patent/JOP20220175A1/ar unknown
- 2022-08-05 CL CL2022002114A patent/CL2022002114A1/es unknown
- 2022-08-05 DO DO2022000159A patent/DOP2022000159A/es unknown
- 2022-08-08 EC ECSENADI202261867A patent/ECSP22061867A/es unknown
- 2022-08-23 CO CONC2022/0011944A patent/CO2022011944A2/es unknown
-
2024
- 2024-07-09 CL CL2024002074A patent/CL2024002074A1/es unknown
- 2024-07-09 CL CL2024002073A patent/CL2024002073A1/es unknown
-
2025
- 2025-06-06 DO DO2025000135A patent/DOP2025000135A/es unknown
- 2025-10-14 JP JP2025172731A patent/JP2026027248A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| IL295291A (en) | 2022-10-01 |
| CR20220441A (es) | 2022-12-14 |
| PE20221781A1 (es) | 2022-11-16 |
| JP2023512827A (ja) | 2023-03-29 |
| CL2024002073A1 (es) | 2025-01-10 |
| CO2022011944A2 (es) | 2022-08-30 |
| WO2021158178A1 (en) | 2021-08-12 |
| MX2022009709A (es) | 2022-09-09 |
| AU2021217919A1 (en) | 2022-09-29 |
| KR20220139930A (ko) | 2022-10-17 |
| PH12022552038A1 (en) | 2023-11-29 |
| DOP2022000159A (es) | 2022-09-30 |
| DOP2025000135A (es) | 2025-07-15 |
| JP2026027248A (ja) | 2026-02-18 |
| CL2024002074A1 (es) | 2025-01-10 |
| EP4100443A1 (en) | 2022-12-14 |
| JOP20220175A1 (ar) | 2022-07-28 |
| EP4100443A4 (en) | 2024-05-15 |
| BR112022015540A2 (pt) | 2022-12-27 |
| US20230080224A1 (en) | 2023-03-16 |
| CL2022002114A1 (es) | 2023-03-03 |
| CN115380050A (zh) | 2022-11-22 |
| CA3170141A1 (en) | 2021-08-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2024001607A1 (es) | Métodos para tratar cánceres y potenciar la eficacia de agentes terapéuticos para el redireccionamiento de células t. | |
| MX2022002977A (es) | Tratamiento y prevencion del cancer usando moleculas de union a antigeno her3. | |
| CO2021009693A2 (es) | Proteínas de unión a antígeno del receptor gamma anti-il2 | |
| PE20211786A1 (es) | Anticuerpos humanizados contra c-kit | |
| CL2011002681A1 (es) | Inmunoconjugado que comprende un agente citotoxico y un anticuerpo humano o humanizado o su fragmento de union a antigeno especifico para mesotelina y que exhibe union invariable a ella; composicion farmaceutica que lo comprende; y su uso para tratar un transtorno o afeccion asociado con la presencia indeseada de mesotelina. | |
| BR112021023026A2 (pt) | Moléculas de ligação biespecíficas anti-ror1/anti-cd3 | |
| CO2018001149A2 (es) | Anticuerpos monoclonales contra bcma | |
| CO2019007823A2 (es) | Anticuerpo anti-cd3 y moléculas que comprenden el anticuerpo | |
| MX2018014456A (es) | Anticuerpos contra alfa-sinucleina y sus usos. | |
| MX2018011035A (es) | Anticuerpos-anti-mica. | |
| UY30525A1 (es) | Agentes de union dirigidos cuyo blanco es el pdgfr-alfa y sus usos | |
| UA103916C2 (xx) | Антитіло проти dkk-1$антитело против dkk-1 | |
| MX2021016098A (es) | Moleculas de anticuerpos humanizados contra cd138 y usos de las mismas. | |
| BRPI0912570B8 (pt) | anticorpo anti-ifn-alfa humanizado, ou um fragmento de ligação ao antígeno do mesmo, composição terapêutica e seus usos | |
| MX2025003354A (es) | Anticuerpos que se unen a 5t4 | |
| CY1126032T1 (el) | Συζευγματα αντισωματος-φαρμακου που στοχευουν uparap | |
| MX2023001707A (es) | Composiciones y métodos para el tratamiento de enfermedades autoinmunes y cánceres por direccionamiento al miembro 8 de la superfamilia de inmunoglobulinas. | |
| AR116897A1 (es) | Métodos para tratar el cáncer con una combinación de un anticuerpo anti-vegf y un conjugado anticuerpo-fármaco anti-factor tisular | |
| MX2025000437A (es) | Inmunoconjugados de epcam y usos de estos | |
| CL2024002074A1 (es) | Molécula de unión a antígeno contra alppl2 y/o alpp, pero no a alpl o alpi. | |
| MX2022004312A (es) | Anticuerpos humanizados anti-receptor tipo quimiocina 1 y sus aplicaciones terapeuticas. | |
| CO2025002301A2 (es) | Anticuerpos anti-ccr8 y métodos de uso | |
| UY37598A (es) | Anticuerpos miméticos de fgf21 y usos de los mismos | |
| JOP20240132A1 (ar) | أجسام مضادة لـ c3 وشظايا ارتباط بمولد الضد منها واستخداماتها لعلاج العين أو الأمراض العينية | |
| MX2021003263A (es) | Combinacion de un antagonista de proteina de muerte programada 1 (pd-1), un inhibidor de ataxia telangiectasia y proteina relacionada con rad3 (atr) y un agente de platino para el tratamiento de cancer. |